BMO Capital Markets maintained its Outperform rating and $545.00 price target on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), representing a 16% upside from the current price of $469.97. With a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback